A case of pulmonary lymphomatoid granulomatosis successfully treated by combination chemotherapy with rituximab

Ki Hwan Jung; Hwa Jung Sung; Ju Han Lee; Ki Yeol Lee; Jae Seung Shin; Kyung Min Kim; Young Sik Kim; Chol Shin; Je Hyeong Kim

doi:10.1159/000237745

A case of pulmonary lymphomatoid granulomatosis successfully treated by combination chemotherapy with rituximab

Ki Hwan Jung, Hwa Jung Sung, Ju Han Lee, Ki Yeol Lee, Jae Seung Shin, Kyung Min Kim, Young Sik Kim, Chol Shin, Je Hyeong Kim

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

Lymphomatoid granulomatosis (LYG) is a rare angiocentric and angiodestructive lymphoproliferative disease characterized by Epstein-Barr virus-positive B cells admixed with reactive T cells. LYG most commonly affects the lung but can also involve other extrapulmonary sites. Pulmonary LYG usually presents as multiple pulmonary nodules with rapid progression and excavation. It can mimic various infectious diseases, vasculitis or metastatic malignancy and is difficult to be diagnosed clinically. Standard treatment for LYG has not yet been established. Despite combination chemotherapy, the overall prognosis is poor. Recently, anti-CD20 monoclonal antibody, rituximab, has been used to treat LYG. We report the case of a 70-year-old male patient with pulmonary LYG, who showed rapid remission of the disease after combination chemotherapy with rituximab.

Original language	English
Pages (from-to)	386-390
Number of pages	5
Journal	Chemotherapy
Volume	55
Issue number	5
DOIs	https://doi.org/10.1159/000237745
Publication status	Published - 2009

Keywords

Combination chemotherapy
Lymphomatoid granulomatosis
Monoclonal antibodies

ASJC Scopus subject areas

Oncology
Pharmacology
Drug Discovery
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000237745

Cite this

@article{c5481878135949a09917ed74b5fa05dc,

title = "A case of pulmonary lymphomatoid granulomatosis successfully treated by combination chemotherapy with rituximab",

abstract = "Lymphomatoid granulomatosis (LYG) is a rare angiocentric and angiodestructive lymphoproliferative disease characterized by Epstein-Barr virus-positive B cells admixed with reactive T cells. LYG most commonly affects the lung but can also involve other extrapulmonary sites. Pulmonary LYG usually presents as multiple pulmonary nodules with rapid progression and excavation. It can mimic various infectious diseases, vasculitis or metastatic malignancy and is difficult to be diagnosed clinically. Standard treatment for LYG has not yet been established. Despite combination chemotherapy, the overall prognosis is poor. Recently, anti-CD20 monoclonal antibody, rituximab, has been used to treat LYG. We report the case of a 70-year-old male patient with pulmonary LYG, who showed rapid remission of the disease after combination chemotherapy with rituximab.",

keywords = "Combination chemotherapy, Lymphomatoid granulomatosis, Monoclonal antibodies",

author = "Jung, {Ki Hwan} and Sung, {Hwa Jung} and Lee, {Ju Han} and Lee, {Ki Yeol} and Shin, {Jae Seung} and Kim, {Kyung Min} and Kim, {Young Sik} and Chol Shin and Kim, {Je Hyeong}",

year = "2009",

doi = "10.1159/000237745",

language = "English",

volume = "55",

pages = "386--390",

journal = "Chemotherapy",

issn = "0009-3157",

publisher = "S. Karger AG",

number = "5",

}

TY - JOUR

T1 - A case of pulmonary lymphomatoid granulomatosis successfully treated by combination chemotherapy with rituximab

AU - Jung, Ki Hwan

AU - Sung, Hwa Jung

AU - Lee, Ju Han

AU - Lee, Ki Yeol

AU - Shin, Jae Seung

AU - Kim, Kyung Min

AU - Kim, Young Sik

AU - Shin, Chol

AU - Kim, Je Hyeong

PY - 2009

Y1 - 2009

N2 - Lymphomatoid granulomatosis (LYG) is a rare angiocentric and angiodestructive lymphoproliferative disease characterized by Epstein-Barr virus-positive B cells admixed with reactive T cells. LYG most commonly affects the lung but can also involve other extrapulmonary sites. Pulmonary LYG usually presents as multiple pulmonary nodules with rapid progression and excavation. It can mimic various infectious diseases, vasculitis or metastatic malignancy and is difficult to be diagnosed clinically. Standard treatment for LYG has not yet been established. Despite combination chemotherapy, the overall prognosis is poor. Recently, anti-CD20 monoclonal antibody, rituximab, has been used to treat LYG. We report the case of a 70-year-old male patient with pulmonary LYG, who showed rapid remission of the disease after combination chemotherapy with rituximab.

AB - Lymphomatoid granulomatosis (LYG) is a rare angiocentric and angiodestructive lymphoproliferative disease characterized by Epstein-Barr virus-positive B cells admixed with reactive T cells. LYG most commonly affects the lung but can also involve other extrapulmonary sites. Pulmonary LYG usually presents as multiple pulmonary nodules with rapid progression and excavation. It can mimic various infectious diseases, vasculitis or metastatic malignancy and is difficult to be diagnosed clinically. Standard treatment for LYG has not yet been established. Despite combination chemotherapy, the overall prognosis is poor. Recently, anti-CD20 monoclonal antibody, rituximab, has been used to treat LYG. We report the case of a 70-year-old male patient with pulmonary LYG, who showed rapid remission of the disease after combination chemotherapy with rituximab.

KW - Combination chemotherapy

KW - Lymphomatoid granulomatosis

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=70049103647&partnerID=8YFLogxK

U2 - 10.1159/000237745

DO - 10.1159/000237745

M3 - Article

C2 - 19752554

AN - SCOPUS:70049103647

SN - 0009-3157

VL - 55

SP - 386

EP - 390

JO - Chemotherapy

JF - Chemotherapy

IS - 5

ER -

A case of pulmonary lymphomatoid granulomatosis successfully treated by combination chemotherapy with rituximab

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this